Risk of Post Transfusion Hepatitis C Virus Infection

NCT00005339 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2016-02-18

No results posted yet for this study

Summary

To determine the risk of transfusion-transmitted hepatitis C virus (HCV) in cardiac surgery patients before and after donor screening for anti-HCV and surrogate markers of non-A, non-B hepatitis (NANBH). Also, to characterize donors who were HCV seronegative and who lacked surrogate markers at the time of donation, but whose recipient seroconverted to HCV.

Conditions

  • Hepatitis, Viral, Human
  • Blood Transfusion
  • Blood Donors

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Eligibility

Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-02-29
Completion
2004-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005339 on ClinicalTrials.gov